NIH Royalties For Pfizer, AstraZeneca, Lilly Drugs Remain Open Question In Repurposing Initiative
This article was originally published in The Pink Sheet Daily
With collaborative research agreement templates that include many of the details for a licensing agreement, royalties will be the major issue to be resolved if researchers develop new IP for one of the firm’s abandoned compounds.
You may also be interested in...
Crowdsourcing among researchers produces several applications proposing to test a few compounds in the NCATS repurposing library for use in multiple new indications, which officials did not expect.
AstraZeneca is giving 15 shelved compounds to U.K.-based academics in a collaboration funded by public money that may produce scientific breakthroughs along with thorny IP issues.
The National Institutes of Health’s National Center for Accelerating Translational Science has opened the pilot round of its compound repurposing effort with 58 drug candidates that will be made available to academic researchers. Half of the 58 have failed in previous studies for neurological indications, a recognized trouble spot for drug development.